Antitumor Activities of Lipophilic Nucleoside 5′-monophosphate Analogues as Prodrugs

Prodrug로서 지질친화성 Nucleoside 5′-(3-pyridinyl carbonyl) monophosphate 유도체의 항암 활성

Several nucleoside 5'-monophosphate analogues and lipophilic nucleoside 5'-(3-pyridinylcarbonyl)monophosphate analogues were synthesized. Antitumor activities of the synthesized nucleoside malogues against P338 mouse leukemia, FM3A murine mammary carcinoma, and U937 human histiocytic lymphoma cells were determined by MTT assay. Antitumor activities of the lipophilic uridine 5'-(3-pyridinylcarbonyl) monophosphate(7) and 2',3'-didehydro-3'-deoxy-thymidine-5'-(3-pyridinylcarbonyl) monophosphate(8) were stronger than those of uridine 5'-monophosphate(1) and 2',3'-didehydro-3'-deoxythymidine-5'-monophosphate(4). This preliminary experimental result suggests that nucleoside 5'-(3-pyridinylcar-bonyl)monophosphate analogues may be new prodrugs to overcome the clinical limit.

몇가지 nucleoside 5'-monophosphate 유도체들과 지질 친화성을 증가시킨 nucleoside 5'-(3-pyridinyl carbonyl)monophosphate 유도체들을 합성한 후 Mouse leukemia P388, Murine mammary carcinoma FM3A, Human histiocytic lymphoma U937 세포들에 대해 시험관내에서 항암활성을 MTT를 이용한 방법으로 나타내었다. 그 결과 uridine 5'-(3-pyridinylcarbonyl) monophosphate(7)와 2',3'-didehydro-3'-deoxythymidine-5' -(3-pyridinylcarbonyl) monophoshate(8)의 inhibition이 uridine 5'-monophosphate(1)와 2',3'-didehydro-3'-deoxythymidine-5'-monophosphate(4) 보다 각각 증가하였다. 이는 nucleoside 5'-(3-pyridinylcarbonyl) monophosphate 유도체들이 임상적 한계를 극복할 수 있는 가능성을 보인 것이다.